Sökresultat

The MultiPark backbone for research interactions is about to be reorganized. Thanks to our members' suggestions, we are now creating 13 special interest groups to address important scientific and technological areas. The process of finding engaged leaders for these groups is about to start, providing opportunities for professional development and network formation to our young scientists. During t

https://www.multipark.lu.se/article/special-interest-groups-open-more-collaboration-within-multipark - 2025-11-21

Huntington’s disease is hereditary, genetic and usually begins between the ages of 30 and 50. In Sweden, around 1,000 people have the diagnosis and several thousand live with the risk of getting the disease. Even more people have a connection to the disease as its symptoms also affect those close to the patient to a high degree. The disease leads to premature death and there are no treatments that

https://www.multipark.lu.se/article/huntingtons-complex-brain-disease-affects-movement-thoughts-and-feelings - 2025-11-21

Since 24 February, nothing has been the same for Ukrainian researchers. In this urgent situation, MultiPark has offered some of them a sanctuary. They are eager to share their thoughts about how we may all contribute to this period to be as constructive as possible, despite the threatening circumstances. It is impossible not to be touched by the horrible situation for the Ukrainian people. As a re

https://www.multipark.lu.se/article/multipark-provides-safe-places-ukrainian-researchers - 2025-11-21

The glymphatic system, which helps clear waste products from the brain, was discovered about a decade ago. Nicholas Bèchet’s project shines light on how it works in Alzheimer’s disease. On June 17, he defends his PhD thesis supervised by Iben Lundgaard at MultiPark. Here, he tells about his discoveries and why we should not compromise on our sleep. Tell us about your research! The glymphatic syste

https://www.multipark.lu.se/article/glymphatic-system-phd-interview-nicholas-bechet - 2025-11-21

The Bundy Academy’s 2022 major prize amounting to SEK 3 million is awarded to Sebastian Palmqvist, Associate Professor of Clinical Memory Research at Lund University and Senior Physician at the Memory Clinic at Skåne University Hospital, for his research on improved diagnostics of Alzheimer’s disease. The Bundy Academy’s 2022 major prize amounting to SEK 3 million was awarded yesterday to Sebastia

https://www.multipark.lu.se/article/awardees-2022-bundy-academy-major-prize - 2025-11-21

Life is like a marathon. According to Dr. Anders Björklund, a pioneer and expert in cell replacement strategies for patients with Parkinson’s Disease, so is life in academia. Along his scientific run he has passed several milestones, the most recent being a jubilee honorary doctorate awarded by Lund University in celebration of his decades of contributions to neuroscience. We sat down with Anders

https://www.multipark.lu.se/article/looking-long-magnificent-road-neuroscientists-life-interview-anders-bjorklund - 2025-11-21

Researchers from Lund University interested in understanding how aging affects the brain have made a new discovery that will help make it easier to study age-related brain diseases and potential treatments in the future. The key to this? human skin cells. The human brain is often likened to the night sky. Look up and one will see billions upon billions of stars. Our brains are similar in that with

https://www.multipark.lu.se/article/how-our-skin-cells-might-be-key-better-understanding-human-brain - 2025-11-21

As the summer holidays approach, we would like to remind all of our scientists about the imminent start of our special interest groups (SIGs). Meetings and activities will start after the summer. So take a look at the SIG in the blue box and contact the convening person to ensure that you are not missing any occasion. We look forward to showcasing the goals and the activities of our SIGs both on t

https://www.multipark.lu.se/article/summer-greetings - 2025-11-21

Researchers at Lund University in Sweden have developed a new method for studying age-related brain disorders. The researchers have focused on the neurodegenerative disorder Huntington’s disease and the results have now been published in the journal Brain. Basic medical research often faces the challenge of developing disease models that correspond to specific disease mechanisms or the disease to

https://www.multipark.lu.se/article/researchers-reprogram-human-skin-cells-aged-neurons-study-neurodegenerative-disorders - 2025-11-21

Marta Ramos’ Ph.D project unravels how inflammation and the glymphatic system affect each other in the brain. September 9, she defends her thesis. Here, she explains how you may complement your thesis project with other missions to boost your career. Tell us about your research! The glymphatic system clears waste products away from the brain via the cerebrospinal fluid (CSF). It consists of a peri

https://www.multipark.lu.se/article/inflammation-and-glymphatic-system-phd-interview-marta-ramos - 2025-11-21

Alzheimer's Association recently released recommendations about using blood-based biomarkers to detect Alzheimer’s disease. The recommendations are based on research conducted by Oskar Hansson, one of MultiPark’s research group leaders. “Blood-based biomarkers for Alzheimer’s are already improving the design of clinical trials, and they are very likely to revolutionize the diagnosis of Alzheimer’s

https://www.multipark.lu.se/article/multipark-researcher-behind-alzheimers-association-recommendations-about-use-alzheimers-blood-tests - 2025-11-21

What is the best approach for treating Alzheimer's disease? Aducanumab is an amyloid beta-directed monoclonal antibody that targets the aggregated forms of amyloid beta found in the brains of people with Alzheimer's disease. In May, Dr. Niklas Mattsson-Carlgren and Dr. Ruben Smith entertained young MultiParkers by debating the pros and cons of using it. Last summer, Aducanumab was approved by the

https://www.multipark.lu.se/article/multipark-debate-aducanumab-yesno - 2025-11-21

The Royal Swedish Academy of Sciences has elected two new members of the Academy’s class for medical sciences. One of them is Malin Parmar, Professor of Cellular Neuroscience at Lund University. Together with her research group, Malin Parmar has conducted several groundbreaking studies on stem cells that have led to the development of new treatments for patients with Parkinson’s disease. Using kno

https://www.multipark.lu.se/article/malin-parmar-elected-royal-swedish-academy-sciences - 2025-11-21

Inflammatory responses in the brain have long been suspected of playing a role in Alzheimer’s disease, but are challenging to monitor in the living human brain. An international collaboration including researchers at MultiPark, Lund University has made it possible to detect elevated levels of Galectin-3, a protein expressed in the immune cells inside the brain. The results were published in Acta N

https://www.multipark.lu.se/article/biomarker-reveals-inflammatory-changes-brain-alzheimers-disease - 2025-11-21

Cell replacement therapy has long been a hope for patients with Parkinson’s disease and efforts are on their way to use stem cell derived-dopaminergic neurons in clinical trials. On 14 October, Jessica Giacomoni defends her thesis. Her project about the direct conversion of human glial cells into therapeutic neurons directly within the brain has the ultimate goal to become an alternative to cell t

https://www.multipark.lu.se/article/turning-glia-neurons-inside-brain-phd-interview-jessica-giacomoni - 2025-11-21

Numerous studies have suggested that eating a healthy diet may reduce a person’s risk of dementia. A new study from one of MultiPark's research groups, published in Neurology, sheds new light on the impact of having a Mediterranean diet. The Mediterranean diet includes a high intake of vegetables, legumes, fruits, fish and healthy fats such as olive oil, and a low intake of dairy products, meats a

https://www.multipark.lu.se/article/does-mediterranean-diet-really-decrease-your-risk-dementia - 2025-11-21

An investigational stem cell-based therapy for the treatment of Parkinson’s Disease, STEM-PD, has been given regulatory approval for a Phase I/IIa clinical trial. Ethical approval of the trial has already been obtained from the Swedish Ethics Review Authority, and the STEM-PD team, led from Lund University in Sweden, is thereby ready to proceed with the trial. “We are excited and looking forward t

https://www.multipark.lu.se/article/swedish-medical-products-agency-grants-approval-clinical-study-new-stem-cell-based-parkinsons - 2025-11-21

Matilde Negrini’s thesis project has been to develop and characterize a rat model of Parkinson’s disease. November 4, she defends her thesis. Here, she talks about her project and most proud moments during her Ph.D. journey. Tell us about your research! My project has been to develop and characterize a rat model of Parkinson’s disease based on the Parkinson’s-related protein alpha-synuclein. This

https://www.multipark.lu.se/article/modelling-parkinsons-disease-phd-interview-matilde-negrini - 2025-11-21

MultiPark’s scientists conduct world-leading research in biomarkers for Alzheimer’s disease, led by Professor Oskar Hansson at the memory clinic at Skåne University Hospital. He recently met with Bill Gates to discuss the future possibilities in this field. You met with Bill Gates yesterday in Brussels. Why did he want to meet you there? Already five years ago, Gill Gates understood the importance

https://www.multipark.lu.se/article/multipark-researcher-bill-gates-brussels - 2025-11-21

A large study led by Lund University in Sweden has shown that people with Alzheimer's disease can now be identified before they experience any symptoms. It is now also possible to predict who will deteriorate within the next few years. The study is published in Nature Medicine, and is very timely in light of the recent development of new drugs for Alzheimer's disease. It has long been known that t

https://www.multipark.lu.se/article/alzheimers-disease-can-be-diagnosed-symptoms-emerge - 2025-11-21